Announcement on Expected Loss in Annual Performance for 2024
Filed with SSE · · 2 pages · Chinese
Jiangsu Cowin Biotech Co., Ltd. on 6ix
Earlier from Jiangsu Cowin Biotech
- Announcement on Voluntary Disclosure of Obtaining Class III Medical Device Registration Certificate for Influenza A/B and Respiratory Syncytial Virus Nucleic Acid Detection Kit
- Announcement on Resignation of Deputy General Manager and Chief Financial Officer
- Announcement on Resolution of the 3rd Extraordinary General Meeting in 2024
- Announcement on Cancellation of Share Options Not Exercised at the End of the 2nd Exercise Period and Failing to Meet Exercise Conditions in the 3rd Exercise Period of the 2021 Stock Option Incentive Plan
- Announcement on Voluntary Disclosure of Obtaining Class III Medical Device Registration Certificate for Helicobacter Pylori Resistance Gene Test Kit
Later from Jiangsu Cowin Biotech
- Announcement on Progress in Repurchasing Shares through Call Auction
- Announcement on Implementation Results of Share Repurchase and Share Changes
- Announcement on Preliminary Earnings Estimate for 2024
- Announcement on Voluntary Disclosure of Obtaining Class III Medical Device Registration Certificate for Human Septin9, SDC2, and NDRG4 Gene Methylation Detection Kit
- 2024 Annual Report
Follow Jiangsu Cowin Biotech into a list and get an email when it puts out news.
Follow Jiangsu Cowin Biotech